Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324402 | 0.88 | HPRT1 (0.35) | ADKHPRT1 | |
| SCHEMBL6902812 | 0.85 | FGFR1 (0.39) | ADKFGFR1SLC22A6HPRT1 | |
| SCHEMBL6320152 | 0.78 | FGFR1 (0.33) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6324436 | 0.77 | FGFR1 (0.34) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6326685 | 0.77 | FGFR1 (0.33) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6321472 | 0.77 | FGFR1 (0.34) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6902586 | 0.73 | HPRT1 (0.43) | ADKFGFR1SLC22A6HPRT1 | |
| SCHEMBL6329303 | 0.72 | ADORA2A (0.46) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6905254 | 0.71 | DNPH1 (0.42) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6904243 | 0.68 | FGFR1 (0.46) | FGFR1SLC22A6HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080053-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | US | claimed |
| US-20050080053-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080053-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, RNASEH1 | ADK 1903/4885FGFR1 3328/4885SLC22A6 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.